Browse the corpus

Buprenorphine-naloxone is a combination medication used in the management and treatment of opioid use disorder, defined by a strong motivation to obtain and use opioids in the face of significant detrimental effects. This activity delves into the intricate interplay between buprenorphine's role as a long-acting partial opioid receptor agonist and naloxone's function as an opioid receptor antagonist. Participating clinicians gain comprehensive insights into the indications, mechanisms of action, and contraindications of buprenorphine-naloxone, with a focus on the efficacy of addressing both illicit and prescription opioid abuse. Topics encompass the mechanism of action, adverse event profile, off-label uses, dosing strategies, pharmacokinetics, monitoring, and relevant drug interactions. By equipping healthcare professionals with this extensive knowledge, this activity aims to empower them to make informed decisions and apply buprenorphine-naloxone effectively in opioid use disorder management. Objectives: Identify the FDA-approved and off-label indications of buprenorphine-naloxone. Select appropriate dosing strategies for buprenorphine-naloxone. Evaluate the adverse effects, contraindications, and potential toxicity associated with buprenorphine-naloxone. Communicate interprofessional team strategies for initiation of buprenorphine-naloxone treatment, perioperative management of individuals on treatment, and management of pregnant women with opioid use disorder. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Buprenorphine overdose typically presents with miosis (eye pupillary constriction), depressed consciousness, and respiratory depression—which, if severe, can result in death.[95] Buprenorphine-naloxone is associated with a much lower likelihood of severe respiratory depression than full mu receptor agonists, such as fentanyl and heroin. Dose-effect studies have found there is a ceiling effect regarding the degree of respiratory depression that buprenorphine can cause.[3][19] This protective ceiling effect is attenuated when buprenorphine is co-administered with benzodiazepines.[1][79][80] Management of Overdose The treatment for opioid-induced respiratory depression is naloxone and ventilatory support. Patients, caregivers, and members of the social support system should be counseled on recognizing and treating respiratory depression. In the hospital setting, the authors have successfully administered 40 mcg of naloxone every 1 to 2 minutes until respiratory and central nervous system depression abates. Administering naloxone in this manner will decrease the severity of opioid withdrawal symptoms. Naloxone is also available in a prefilled syringe for intramuscular injection and as an over-the-counter nasal spray.[96] Due to the short duration of action, patients may require repeated doses or the initiation of a naloxone infusion. The combination medication buprenorphine-naloxone is not an appropriate treatment for opioid-induced respiratory depression.

Opioid use disorder is a significant public health problem. Buprenorphine-naloxone is one of the most effective medications to treat opioid use disorder. Coordination of effective interprofessional team communication is essential for patients to safely initiate therapy, decrease harm, reduce the risk of relapse, and ensure care is provided. Social workers, mental health therapists, and psychiatrists serve an instrumental role in identifying patients who may benefit from buprenorphine-naloxone therapy. After therapy has begun, social workers, therapists, and psychiatrists are essential components of the safety net required to monitor for diversion, medication toxicity, withdrawal symptoms, dosing compliance, and concurrent psychiatric disorders. According to section 1262 of the Consolidated Appropriations Act of 2023, all clinicians with Drug Enforcement Administration (DEA) authority for schedule III medications can prescribe buprenorphine-naloxone. Many state nurse practitioners and physician assistants may prescribe buprenorphine-naloxone to increase access. Although the prescription of buprenorphine for opioid use disorder requires the clinician to obtain a waiver from Substance Abuse and Mental Health Services (SAMHSA), buprenorphine for chronic pain does not require a waiver.[13] A study utilized a quasi-experimental design to assess a new 4-hour Medication-Assisted Treatment training program tailored for primary care clinicians as an addition to the standard 8-hour SAMHSA DATA 2000 waiver training. Evaluating 183 participants, pretraining and posttraining assessments revealed notable improvements in clinicians' confidence and competence in implementing medication-assisted treatment, indicating the potential efficacy of the supplemental training. Further research to confirm these findings and explore broader policy implications is recommended for wider adoption.[97] These clinicians are ultimately responsible for ethical considerations like determining who should be treated, ensuring that the patient understands the adverse effects and the benefits of treatment, and obtaining informed consent.

Evaluating 183 participants, pretraining and posttraining assessments revealed notable improvements in clinicians' confidence and competence in implementing medication-assisted treatment, indicating the potential efficacy of the supplemental training. Further research to confirm these findings and explore broader policy implications is recommended for wider adoption.[97] These clinicians are ultimately responsible for ethical considerations like determining who should be treated, ensuring that the patient understands the adverse effects and the benefits of treatment, and obtaining informed consent. Pharmacists are essential for assessing drug-drug interactions and providing guidance on the initial dose, maintenance dose, and required dosing adjustments due to changes in organ system function and comorbidities. Nurses are often the first to field patient questions about the dosing regimen and patient concerns related to adverse effects. Laboratory technicians and medical assistants reduce the risk of adverse effects through their role in monitoring organ function. In cases of severe overdose, individuals should be hospitalized in the medical intensive care unit, necessitating supervision by critical care clinicians. Successful treatment of opioid use disorder requires interprofessional care coordination.[98] Each team member must draw upon their unique experiences, knowledge, and skills to create a care plan that minimizes adverse drug reactions, enhances safety, and increases the likelihood of treatment retention. By leveraging a multidisciplinary approach, personalized care plans can be crafted for patients, mitigating the adverse effects of buprenorphine-naloxone and potentially enhancing the overall quality of life for individuals undergoing treatment.